| Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study A Rauch, Z Kutalik, P Descombes, T Cai, J Di Iulio, T Mueller, M Bochud, ... Gastroenterology 138 (4), 1338-1345. e7, 2010 | 1525 | 2010 |
| Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift E Cameroni, JE Bowen, LE Rosen, C Saliba, SK Zepeda, K Culap, ... Nature 602 (7898), 664-670, 2022 | 1128 | 2022 |
| N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 M McCallum, A De Marco, FA Lempp, MA Tortorici, D Pinto, AC Walls, ... Cell 184 (9), 2332-2347. e16, 2021 | 863 | 2021 |
| Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity EC Thomson, LE Rosen, JG Shepherd, R Spreafico, A da Silva Filipe, ... Cell 184 (5), 1171-1187. e20, 2021 | 561 | 2021 |
| SARS-CoV-2 immune evasion by the B. 1.427/B. 1.429 variant of concern M McCallum, J Bassi, A De Marco, A Chen, AC Walls, J Di Iulio, ... Science 373 (6555), 648-654, 2021 | 511 | 2021 |
| Deep sequencing of 10,000 human genomes A Telenti, LCT Pierce, WH Biggs, J Di Iulio, EHM Wong, MM Fabani, ... Proceedings of the National Academy of Sciences 113 (42), 11901-11906, 2016 | 409 | 2016 |
| BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment GE Winter, A Mayer, DL Buckley, MA Erb, JE Roderick, S Vittori, JM Reyes, ... Molecular cell 67 (1), 5-18. e19, 2017 | 399 | 2017 |
| SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape TN Starr, N Czudnochowski, Z Liu, F Zatta, YJ Park, A Addetia, D Pinto, ... Nature 597 (7874), 97-102, 2021 | 393 | 2021 |
| Native elongating transcript sequencing reveals human transcriptional activity at nucleotide resolution A Mayer, J Di Iulio, S Maleri, U Eser, J Vierstra, A Reynolds, R Sandstrom, ... Cell 161 (3), 541-554, 2015 | 375 | 2015 |
| Broad betacoronavirus neutralization by a stem helix–specific human antibody D Pinto, MM Sauer, N Czudnochowski, JS Low, MA Tortorici, MP Housley, ... Science 373 (6559), 1109-1116, 2021 | 292 | 2021 |
| Human gene essentiality I Bartha, J Di Iulio, JC Venter, A Telenti Nature Reviews Genetics 19 (1), 51-62, 2018 | 233 | 2018 |
| The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2 AL Cathcart, C Havenar-Daughton, FA Lempp, D Ma, MA Schmid, ... biorxiv, 2021.03. 09.434607, 2021 | 213 | 2021 |
| Broad sarbecovirus neutralization by a human monoclonal antibody MA Tortorici, N Czudnochowski, TN Starr, R Marzi, AC Walls, F Zatta, ... Nature 597 (7874), 103-108, 2021 | 206 | 2021 |
| In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function J di Iulio, A Fayet, M Arab-Alameddine, M Rotger, R Lubomirov, ... Pharmacogenetics and genomics 19 (4), 300-309, 2009 | 190 | 2009 |
| Imprinted antibody responses against SARS-CoV-2 Omicron sublineages YJ Park, D Pinto, AC Walls, Z Liu, A De Marco, F Benigni, F Zatta, ... Science 378 (6620), 619-627, 2022 | 165 | 2022 |
| Pharmacogenetics‐based population pharmacokinetic analysis of efavirenz in HIV‐1‐infected individuals M Arab‐Alameddine, J Di Iulio, T Buclin, M Rotger, R Lubomirov, ... Clinical Pharmacology & Therapeutics 85 (5), 485-494, 2009 | 160 | 2009 |
| The human noncoding genome defined by genetic diversity J Di Iulio, I Bartha, EHM Wong, HC Yu, V Lavrenko, D Yang, I Jung, ... Nature genetics 50 (3), 333-337, 2018 | 158 | 2018 |
| Predicting the mutational drivers of future SARS-CoV-2 variants of concern MC Maher, I Bartha, S Weaver, J Di Iulio, E Ferri, L Soriaga, FA Lempp, ... Science translational medicine 14 (633), eabk3445, 2022 | 130 | 2022 |
| ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir R Lubomirov, J di Iulio, A Fayet, S Colombo, R Martinez, C Marzolini, ... Pharmacogenetics and genomics 20 (4), 217-230, 2010 | 129 | 2010 |
| Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study R Lubomirov, S Colombo, J di Iulio, B Ledergerber, R Martinez, ... Journal of infectious diseases 203 (2), 246-257, 2011 | 122 | 2011 |
